• 1. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 4. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

• Solvents and Organic Chemicals Organic Compounds Benzenoids Fluorenes Fluorenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Fluorenes
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Comprehensive Guide to Fmoc-Arg(Mtr)-OH (CAS No. 98930-01-9): Properties, Applications, and Industry Insights

Fmoc-Arg(Mtr)-OH (CAS No. 98930-01-9) is a critically important amino acid derivative widely used in peptide synthesis, particularly in solid-phase peptide synthesis (SPPS). This compound belongs to the Fmoc-protected amino acids family, where the Fmoc (9-fluorenylmethoxycarbonyl) group serves as a temporary protecting group for the alpha-amino functionality, while the Mtr (4-methoxy-2,3,6-trimethylbenzenesulfonyl) group protects the guanidine side chain of arginine. The unique combination of these protecting groups makes Fmoc-Arg(Mtr)-OH a preferred choice for researchers working on complex peptide sequences that require precise control over side-chain reactivity.

In recent years, the demand for Fmoc-protected amino acids has surged due to the growing interest in therapeutic peptides and bioconjugation technologies. The pharmaceutical industry, in particular, has shown increased attention to peptide-based drug development, with Fmoc-Arg(Mtr)-OH playing a crucial role in synthesizing peptide fragments for drug discovery and biomedical research. The compound's stability under standard SPPS conditions and its compatibility with various coupling reagents make it indispensable for modern peptide chemistry laboratories.

The chemical properties of Fmoc-Arg(Mtr)-OH (CAS No. 98930-01-9) deserve special attention. With a molecular formula of C₃₂H₃₆N₄O₇S and a molecular weight of 620.72 g/mol, this white to off-white powder typically shows excellent solubility in polar aprotic solvents like N,N-dimethylformamide (DMF) and dimethyl sulfoxide (DMSO), which are commonly used in peptide synthesis. The Mtr protecting group offers superior stability during Fmoc-deprotection steps while being selectively removable under mild acidic conditions, making it ideal for synthesizing peptides containing multiple arginine residues.

Current research trends highlight the importance of Fmoc-Arg(Mtr)-OH in developing COVID-19-related peptide inhibitors and other antiviral compounds. Many researchers are exploring its potential in creating peptide mimics that can interfere with viral entry mechanisms. This application has significantly increased the visibility of 98930-01-9 in scientific literature and patent applications, particularly in studies focusing on protein-protein interactions and receptor binding domains.

Quality control aspects of Fmoc-Arg(Mtr)-OH are frequently discussed in scientific forums. Reputable manufacturers typically provide comprehensive analytical data including HPLC purity (>98%), 1H NMR and 13C NMR spectra, and mass spectrometry verification. Proper storage conditions (typically at -20°C under inert atmosphere) are crucial for maintaining the compound's stability, as the Fmoc group can be sensitive to prolonged exposure to moisture and elevated temperatures.

The synthesis of Fmoc-Arg(Mtr)-OH involves multiple steps of selective protection and deprotection chemistry. First, the guanidine group of arginine is protected with the Mtr group, followed by protection of the alpha-amino group with the Fmoc moiety. This sequential protection strategy ensures high yield and purity of the final product. Recent advancements in green chemistry approaches have led to improved synthetic routes that reduce environmental impact while maintaining high efficiency.

In the context of peptide drug manufacturing, regulatory considerations for Fmoc-Arg(Mtr)-OH are becoming increasingly important. The compound must meet stringent quality standards set by pharmacopeias when used in GMP peptide synthesis. Many contract manufacturing organizations (CMOs) specializing in peptide production maintain detailed documentation for 98930-01-9 to ensure compliance with ICH guidelines and other regulatory requirements.

Emerging applications of Fmoc-Arg(Mtr)-OH extend beyond traditional peptide synthesis. Researchers are exploring its use in peptide nanomaterials, drug delivery systems, and even in the development of peptide-based biosensors. The compound's ability to introduce positively charged arginine residues into synthetic peptides makes it valuable for creating materials with specific electrostatic properties and biocompatibility characteristics.

For laboratories working with Fmoc-Arg(Mtr)-OH, proper handling and disposal procedures are essential. While not classified as hazardous, standard precautions for handling fine chemical powders should be followed, including the use of appropriate personal protective equipment (PPE) such as gloves and safety glasses. The compound should be stored away from strong acids, bases, and oxidizing agents to prevent decomposition of the protecting groups.

The market for Fmoc-protected amino acids including Fmoc-Arg(Mtr)-OH is expected to grow significantly in the coming years, driven by increasing R&D investments in peptide therapeutics and personalized medicine. As peptide synthesis technologies continue to advance, the demand for high-purity, reliably protected amino acid building blocks like 98930-01-9 will likely increase, particularly in academic research institutions and biopharmaceutical companies focusing on innovative drug modalities.

• 61315-61-5(Boc-D-Arg(Tos)-OH)
• 77128-72-4(Fmoc-tyr(ME)-OH)
• 91000-69-0(Fmoc-Arg-OH)
• 80745-09-1(Z-Arg(Mtr)-OH CHA)
• 80745-10-4(H-Arg(Mtr)-OH H2O)
• 4353-32-6(H-Arg(Tos)-OH)
• 13836-37-8(Boc-Arg(Tos)-OH)
• 83792-47-6(N2-(((9H-Fluoren-9-yl)methoxy)carbonyl)-Nw-tosyl-L-arginine)
• 88743-97-9(N-Alpha-Fmoc-N-g-(mesitylene-2-sulfonyl)-L-arginine)
• 154445-77-9(Fmoc-Arg(Pbf)-OH)